Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207554 | 1.00 | CYP2E1 (0.53) | CYP2E1NR1I2RAF1NR1H4BRD4 | |
| SCHEMBL15498380 | 0.91 | CYP2E1 (0.63) | CYP2E1NR1I2PDK1 | |
| SCHEMBL15498235 | 0.91 | CYP2E1 (0.63) | CYP2E1NR1I2PDK1 | |
| SCHEMBL15511425 | 0.91 | CYP2E1 (0.63) | CYP2E1NR1I2PDK1 | |
| SCHEMBL674344 | 0.85 | CYP2E1 (0.53) | CYP2E1NR1I2NR1H4 | |
| SCHEMBL675371 | 0.85 | CYP2E1 (0.53) | CYP2E1NR1I2NR1H4ALDH1A1 | |
| SCHEMBL669376 | 0.85 | CYP2E1 (0.53) | CYP2E1NR1I2NR1H4ALDH1A1 | |
| SCHEMBL672579 | 0.84 | CYP2E1 (0.54) | CYP2E1NR1I2NR1H4 | |
| SCHEMBL672580 | 0.84 | CYP2E1 (0.54) | CYP2E1NR1I2NR1H4 | |
| SCHEMBL669432 | 0.83 | CYP2E1 (0.57) | CYP2E1NR1I2NR1H4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | CYP2E1 275/4885NR1I2 1347/4885RAF1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.